1037754-73-6 Usage
Description
tert-butyl 4-((R)-3-hydroxy-1-methylpropyl)piperidine-1-carboxylate is a complex organic compound with a specific molecular structure. It is characterized by its unique arrangement of atoms and functional groups, which contribute to its potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
tert-butyl 4-((R)-3-hydroxy-1-methylpropyl)piperidine-1-carboxylate is used as a key intermediate in the synthesis of pyrrolidine derivatives for the treatment of metabolic disorders. Its unique molecular structure allows for the development of therapeutic agents that can help manage and treat these conditions effectively.
Used in Drug Development for GPR119 Modulation:
tert-butyl 4-((R)-3-hydroxy-1-methylpropyl)piperidine-1-carboxylate is also used as a therapeutic modulator of GPR119 activity. GPR119 is a G-protein coupled receptor that plays a role in glucose homeostasis and insulin secretion. By modulating GPR119 activity, this compound can potentially contribute to the development of novel treatments for diabetes and other related metabolic conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1037754-73-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,7,5 and 4 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1037754-73:
(9*1)+(8*0)+(7*3)+(6*7)+(5*7)+(4*5)+(3*4)+(2*7)+(1*3)=156
156 % 10 = 6
So 1037754-73-6 is a valid CAS Registry Number.
1037754-73-6Relevant articles and documents
PIPERIDINYL GPCR AGONISTS
-
Page/Page column 16, (2010/04/03)
Compounds of formula (I):or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.
HETEROCYCLIC GPCR AGONISTS
-
Page/Page column 23, (2010/04/03)
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.
COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
-
Page/Page column 20, (2009/04/25)
The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.
